Redwood Pharma AB is a company whose mission is to develop new ophthalmic pharmaceutical therapies where there are large and unmet market needs. It has in-licensed, IntelliGel, a proprietary and patented hydrogel drug delivery platform technology that will reduce dosages, dosing-frequency and, thereby, potential systemic toxicities of active pharmaceutical ingredients. The Company’s lead development product is a new therapy to treat chronic Dry Eye Disease (DED) in post-menopausal women. With an ageing population, DED affects more and more people hindering many in their daily activities such as reading, using a computer and driving an automobile.
June 27, 2016 – Redwood Pharma och SP Process Development inleder samarbete
June 15, 2016 – Idag inleds handeln i Redwood Pharma (REDW) på AktieTorget
June 7, 2016 – Redwood Pharma to Present at BIO 2016 in San Francisco
June 7, 2016 – Redwood Pharma presenterar på BIO 2016 i San Francisco
June 2, 2016 – Redwood Pharma noteras på AktieTorget och stärker kassan
May 13, 2016 – Redwood Pharma genomför nyemission inför listning på AktieTorget